Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 47 | 2024 | 842 | 12.350 |
Why?
|
| Kidney Failure, Chronic | 44 | 2024 | 865 | 11.430 |
Why?
|
| Peritoneal Dialysis | 9 | 2023 | 118 | 5.580 |
Why?
|
| Medicare | 17 | 2023 | 424 | 3.570 |
Why?
|
| Prospective Payment System | 5 | 2021 | 16 | 2.440 |
Why?
|
| United States | 43 | 2024 | 10631 | 2.050 |
Why?
|
| Ambulatory Care | 5 | 2021 | 377 | 2.000 |
Why?
|
| Hemodialysis, Home | 4 | 2022 | 13 | 1.970 |
Why?
|
| Economic Competition | 4 | 2023 | 14 | 1.780 |
Why?
|
| Nephrologists | 3 | 2021 | 13 | 1.560 |
Why?
|
| Ambulatory Care Facilities | 6 | 2021 | 229 | 1.550 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 607 | 1.500 |
Why?
|
| Health Facility Closure | 2 | 2021 | 8 | 1.460 |
Why?
|
| Renal Insufficiency | 3 | 2023 | 233 | 1.430 |
Why?
|
| Health Care Sector | 3 | 2020 | 19 | 1.430 |
Why?
|
| Health Policy | 4 | 2020 | 212 | 1.420 |
Why?
|
| Patient Readmission | 4 | 2017 | 366 | 1.290 |
Why?
|
| Reimbursement Mechanisms | 4 | 2023 | 38 | 1.220 |
Why?
|
| Hematinics | 2 | 2023 | 57 | 1.190 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 711 | 1.120 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2024 | 94 | 1.100 |
Why?
|
| Fee-for-Service Plans | 2 | 2016 | 18 | 1.080 |
Why?
|
| Nephrology | 3 | 2019 | 144 | 1.070 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 477 | 1.060 |
Why?
|
| Medicaid | 6 | 2019 | 245 | 1.050 |
Why?
|
| Health Expenditures | 4 | 2022 | 103 | 0.990 |
Why?
|
| Financing, Government | 2 | 2023 | 30 | 0.970 |
Why?
|
| Anemia | 2 | 2023 | 340 | 0.930 |
Why?
|
| Aged | 26 | 2024 | 19080 | 0.930 |
Why?
|
| Humans | 64 | 2024 | 123163 | 0.930 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2014 | 16 | 0.890 |
Why?
|
| Hospitalization | 4 | 2021 | 1726 | 0.890 |
Why?
|
| Benzazepines | 2 | 2014 | 64 | 0.870 |
Why?
|
| Vitamin D | 2 | 2018 | 159 | 0.870 |
Why?
|
| Registries | 8 | 2022 | 1392 | 0.850 |
Why?
|
| National Health Programs | 1 | 2023 | 19 | 0.840 |
Why?
|
| Health Care Costs | 3 | 2020 | 366 | 0.750 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 7 | 0.730 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2020 | 715 | 0.710 |
Why?
|
| Insurance, Health | 2 | 2018 | 138 | 0.690 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2020 | 9 | 0.690 |
Why?
|
| Health Facility Merger | 2 | 2019 | 10 | 0.690 |
Why?
|
| Middle Aged | 24 | 2024 | 25992 | 0.680 |
Why?
|
| Safety-net Providers | 1 | 2019 | 43 | 0.660 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 714 | 0.660 |
Why?
|
| Reimbursement, Incentive | 2 | 2023 | 47 | 0.650 |
Why?
|
| Specialization | 1 | 2019 | 76 | 0.640 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 628 | 0.630 |
Why?
|
| Models, Organizational | 1 | 2019 | 40 | 0.630 |
Why?
|
| Male | 34 | 2024 | 60082 | 0.620 |
Why?
|
| Nurse Practitioners | 1 | 2019 | 43 | 0.620 |
Why?
|
| Physician Assistants | 1 | 2019 | 59 | 0.610 |
Why?
|
| Commerce | 1 | 2018 | 51 | 0.600 |
Why?
|
| Female | 34 | 2024 | 65489 | 0.590 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 115 | 0.580 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 122 | 0.570 |
Why?
|
| Physicians | 2 | 2023 | 584 | 0.560 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 1863 | 0.550 |
Why?
|
| Telemedicine | 1 | 2023 | 426 | 0.550 |
Why?
|
| Insurance Coverage | 1 | 2017 | 121 | 0.540 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 207 | 0.540 |
Why?
|
| Hemoglobins | 2 | 2023 | 301 | 0.520 |
Why?
|
| Mobility Limitation | 1 | 2015 | 23 | 0.500 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 5 | 0.490 |
Why?
|
| Vascular Access Devices | 1 | 2014 | 35 | 0.470 |
Why?
|
| Office Visits | 1 | 2015 | 76 | 0.460 |
Why?
|
| Health Resources | 1 | 2015 | 116 | 0.440 |
Why?
|
| Pravastatin | 1 | 2013 | 23 | 0.430 |
Why?
|
| Cohort Studies | 8 | 2019 | 4705 | 0.420 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 481 | 0.420 |
Why?
|
| Rhabdomyolysis | 1 | 2013 | 35 | 0.420 |
Why?
|
| Health Care Reform | 3 | 2020 | 50 | 0.410 |
Why?
|
| Cost-Benefit Analysis | 4 | 2019 | 501 | 0.390 |
Why?
|
| Hyperparathyroidism | 1 | 2010 | 24 | 0.360 |
Why?
|
| Naphthalenes | 1 | 2010 | 37 | 0.360 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 455 | 0.360 |
Why?
|
| Residence Characteristics | 1 | 2013 | 269 | 0.360 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 418 | 0.350 |
Why?
|
| Ownership | 3 | 2019 | 30 | 0.350 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 1414 | 0.340 |
Why?
|
| Retrospective Studies | 10 | 2024 | 16021 | 0.310 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 596 | 0.310 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 162 | 0.310 |
Why?
|
| Adult | 12 | 2024 | 29057 | 0.300 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2013 | 105 | 0.300 |
Why?
|
| Cost Savings | 2 | 2020 | 69 | 0.290 |
Why?
|
| Time Factors | 7 | 2019 | 6217 | 0.280 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1070 | 0.280 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 849 | 0.280 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 794 | 0.270 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 1000 | 0.250 |
Why?
|
| Stroke | 1 | 2013 | 958 | 0.240 |
Why?
|
| Forearm | 1 | 2024 | 44 | 0.240 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3378 | 0.230 |
Why?
|
| Ferritins | 1 | 2023 | 96 | 0.210 |
Why?
|
| Markov Chains | 2 | 2013 | 83 | 0.210 |
Why?
|
| Disease Progression | 3 | 2013 | 2026 | 0.210 |
Why?
|
| Travel | 1 | 2023 | 117 | 0.200 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 94 | 0.200 |
Why?
|
| Patient Care Bundles | 1 | 2021 | 23 | 0.190 |
Why?
|
| Iron | 1 | 2023 | 261 | 0.180 |
Why?
|
| Neoplasms | 1 | 2015 | 2757 | 0.180 |
Why?
|
| Propensity Score | 1 | 2021 | 207 | 0.180 |
Why?
|
| China | 1 | 2021 | 240 | 0.180 |
Why?
|
| Health Facilities, Proprietary | 1 | 2019 | 3 | 0.170 |
Why?
|
| Data Collection | 1 | 2022 | 386 | 0.170 |
Why?
|
| Benzofurans | 1 | 2019 | 24 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2022 | 12129 | 0.170 |
Why?
|
| Logistic Models | 2 | 2016 | 1793 | 0.170 |
Why?
|
| Quinoxalines | 1 | 2019 | 39 | 0.170 |
Why?
|
| Medically Uninsured | 1 | 2019 | 73 | 0.160 |
Why?
|
| Patient Care | 1 | 2020 | 100 | 0.160 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 48 | 0.160 |
Why?
|
| Ezetimibe | 1 | 2019 | 95 | 0.160 |
Why?
|
| Decision Support Techniques | 2 | 2013 | 280 | 0.160 |
Why?
|
| Indians, North American | 1 | 2018 | 58 | 0.160 |
Why?
|
| Outpatients | 1 | 2020 | 253 | 0.150 |
Why?
|
| Imidazoles | 1 | 2019 | 199 | 0.150 |
Why?
|
| Risk Factors | 4 | 2018 | 10008 | 0.150 |
Why?
|
| Central Venous Catheters | 1 | 2018 | 38 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 593 | 0.150 |
Why?
|
| Policy Making | 1 | 2018 | 59 | 0.150 |
Why?
|
| Employment | 1 | 2018 | 67 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2018 | 284 | 0.140 |
Why?
|
| Program Development | 1 | 2018 | 190 | 0.140 |
Why?
|
| Physician's Role | 1 | 2019 | 164 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2023 | 752 | 0.140 |
Why?
|
| Hospitals | 1 | 2019 | 396 | 0.140 |
Why?
|
| Cause of Death | 1 | 2018 | 458 | 0.130 |
Why?
|
| Graft Survival | 1 | 2018 | 525 | 0.130 |
Why?
|
| Kidney | 4 | 2024 | 1337 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2018 | 449 | 0.130 |
Why?
|
| Heart Transplantation | 1 | 2022 | 854 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2016 | 279 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 323 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 1168 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2019 | 548 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2019 | 747 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 143 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2020 | 625 | 0.110 |
Why?
|
| Risk | 2 | 2013 | 747 | 0.110 |
Why?
|
| Public Health | 1 | 2016 | 261 | 0.110 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1026 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2013 | 50 | 0.110 |
Why?
|
| Young Adult | 4 | 2019 | 8862 | 0.110 |
Why?
|
| Drug Costs | 1 | 2013 | 61 | 0.100 |
Why?
|
| Hypertension, Renal | 1 | 2012 | 37 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 1151 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 176 | 0.100 |
Why?
|
| Heparin | 1 | 2014 | 227 | 0.100 |
Why?
|
| Proteinuria | 1 | 2012 | 110 | 0.100 |
Why?
|
| Age of Onset | 1 | 2013 | 581 | 0.100 |
Why?
|
| Morbidity | 1 | 2012 | 241 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2013 | 164 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2016 | 478 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1305 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 374 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1683 | 0.090 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2015 | 532 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2014 | 459 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2016 | 518 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2014 | 485 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 1005 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2013 | 1243 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2127 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 6371 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 428 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1259 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2014 | 581 | 0.080 |
Why?
|
| Hypertension | 1 | 2013 | 1287 | 0.060 |
Why?
|
| Arm | 1 | 2024 | 76 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5046 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2394 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 314 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2023 | 519 | 0.040 |
Why?
|
| Carbamates | 1 | 2019 | 57 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 67 | 0.040 |
Why?
|
| Amides | 1 | 2019 | 83 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 132 | 0.040 |
Why?
|
| Unemployment | 1 | 2018 | 20 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2019 | 241 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2019 | 259 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2018 | 209 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 19102 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 132 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2016 | 134 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 116 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 2541 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 705 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1496 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 2838 | 0.020 |
Why?
|
| South Carolina | 1 | 2011 | 10 | 0.020 |
Why?
|
| Georgia | 1 | 2011 | 29 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 58 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 2802 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 107 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 771 | 0.020 |
Why?
|
| Veterans | 1 | 2019 | 1726 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2011 | 391 | 0.020 |
Why?
|